Medical Devices UK

UK Automated Insulin Delivery Systems Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

UK Automated Insulin Delivery Systems Market Industry Trends and Forecast to 2034: Segmented by (Component, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UK · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $70.7 Mn Placeholder estimate
Estimate 2025 $81.0 Mn 2.3% of the global market
Projected 2034 $278.5 Mn 243.6% Adds $197.4 Mn over 9 forecast years
CAGR 2025–2034 14.7% Faster than 90% of 180 Medical Devices markets here
Key players 6 +1
  • UK is 2.28% of the global market.
  • In Europe, the largest is Germany at $111.6 Mn.
  • Fastest growing: Russia at 17% a year.
  • UK ranks 3rd of 6 by size in Europe.

Market size projection

UK

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$197.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Automated Insulin Delivery Systems Market market size by year, UK
YearMarket sizeChange that yearSince 2025
2024 (estimate) $70.7 Mn — —
2025 (base) $81.0 Mn +$10.4 Mn —
2026 (forecast) $93.0 Mn +$11.9 Mn +14.7%
2027 (forecast) $106.6 Mn +$13.7 Mn +31.6%
2028 (forecast) $122.3 Mn +$15.7 Mn +50.9%
2029 (forecast) $140.3 Mn +$18.0 Mn +73.1%
2030 (forecast) $160.9 Mn +$20.6 Mn +98.5%
2031 (forecast) $184.5 Mn +$23.7 Mn +127.7%
2032 (forecast) $211.7 Mn +$27.1 Mn +161.2%
2033 (forecast) $242.8 Mn +$31.1 Mn +199.6%
2034 (forecast) $278.5 Mn +$35.7 Mn +243.6%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

UK Automated Insulin Delivery Systems Market Analysis at a glance
Market size, 2025$81.0 Mn placeholder estimate
Forecast, 2034$278.5 Mn placeholder estimate
Growth (CAGR), 2025–203414.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsComponent, type and end user (see all)
Key playersMedtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and 1 more (see all)
Regulator in the UKMHRASource: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
Active clinical trials44 in the UKSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The UK Automated Insulin Delivery Systems Market Analysis Executive Summary

Automated insulin delivery systems link an insulin pump with a glucose sensor and software that adjusts insulin doses automatically.

Key segments of the automated Insulin Delivery Systems market include component (Insulin Pumps, CGM Sensors and Control Algorithms) and type (Hybrid Closed Loop and Advanced Hybrid Closed Loop).

Bar chart: UK Automated Insulin Delivery Systems market size, 2024–2034, placeholder estimates. $70.7 Mn in 2024, $81.0 Mn in 2025 and $278.5 Mn in 2034, 14.7% CAGR.
UK Automated Insulin Delivery Systems market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

UK Automated Insulin Delivery Systems Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the automated Insulin Delivery Systems market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the automated Insulin Delivery Systems market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Automated Insulin Delivery Systems Market in the UK

The automated Insulin Delivery Systems market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Automated Insulin Delivery Systems Market in the UK

Automated Insulin Delivery Systems in the UK: rules, payment and research

Medical devices sold in Great Britain need UKCA or CE marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA).⁠[1] The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund.⁠[2] ClinicalTrials.gov lists 44 studies on Automated Insulin Delivery Systems that are recruiting, active or about to start in the UK.⁠[3] Diabetes (adults): 8.8% of adults in 2022, the latest WHO figure for the UK.⁠[4]

[1] Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.

[2] National Institute for Health and Care Excellence. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 20 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how automated Insulin Delivery Systems products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in the UK.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Automated Insulin Delivery Systems right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 20 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Automated Insulin Delivery Systems in context

The UK compared

  • Diabetes (adults, WHO): 8.8% of adults (2022). World: 14.1% of adults (2022). 3rd highest of the 13 countries we cover in Europe.[1]
  • Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 7th highest of the 13 countries we cover in Europe.[2]
  • Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 11th highest of the 13 countries we cover in Europe.[3]

[1] WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 20 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 19 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

Free data on this topic

Inside the UK

Quick answers

Frequently asked questions

How big is the Automated Insulin Delivery Systems market in the UK?
Placeholder estimate: about $81.0 Mn in 2025, rising to about $278.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Automated Insulin Delivery Systems market in the UK growing?
Placeholder estimate: about 14.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Automated Insulin Delivery Systems market report cover?
The report splits the market by component (Insulin Pumps, CGM Sensors, Control Algorithms), type (Hybrid Closed Loop, Advanced Hybrid Closed Loop) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Automated Insulin Delivery Systems market?
Key players include Medtronic, Tandem Diabetes Care, Insulet Corporation, Dexcom, Inc., Abbott Laboratories and Beta Bionics.
What is driving the Automated Insulin Delivery Systems market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the automated Insulin Delivery Systems market.
Who regulates Automated Insulin Delivery Systems in the UK?
Medical devices sold in Great Britain need UKCA or CE marking and registration with the Medicines and Healthcare products Regulatory Agency (MHRA). Source: Medicines and Healthcare products Regulatory Agency. Checked 14 Nov 2026.
How is healthcare paid for in the UK?
The NHS gives care that is free at the point of use; in England, NICE advises which medicines and treatments the NHS should fund. Source: National Institute for Health and Care Excellence. Checked 14 Nov 2026.
How many clinical trials on Automated Insulin Delivery Systems are running in the UK?
44 studies are recruiting, active or about to start in the UK, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.
What does WHO report for the UK?
Diabetes (adults): 8.8% of adults in 2022, the latest WHO figure. Source: WHO Global Health Observatory, Diabetes (adults, WHO) (% of adults). Retrieved 20 Nov 2026.
How many people in the UK are 65 or older?
19.7% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 19 Nov 2026.
Back to Catalogue

Related Medical Devices reports in UK

See all

Related on diabetes and remote monitoring and wearables

See the topic